VANCOUVER, WASHINGTON, December 23, 2022 (GLOBE NEWSWIRE) — Cytodyne Co., Ltd. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with potential for multiple indications, announced on December 29, 2022 at 8:00 am ET We will host a webcast at 11:00 am. We discuss his leronlimab performance in clinical trials and the recent indictment against his former CEO, Nader Pourhassan, who was dismissed on January 24, 2022 and has had nothing to do with the company since.
Webcast access information
Replays will be available approximately 60 minutes after the webcast ends and can be accessed through the link above through January 29, 2023.
CytoDyn develops and commercializes leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) designed to bind to CC chemokine receptor type 5 (CCR5), a specific immune system surface protein. A clinical-stage biotechnology company focused on biotechnology. Cells thought to play a role in many disease processes. CytoDyn is investigating leronlimab in multiple therapeutic areas, including infectious diseases, cancer and autoimmune diseases.
Christina de Leon